Vaxxinity, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
	10-K	10-K	10-K	S-1/A
Revenues	0.0	0.1	0.6	0.0
Revenue growth	-100.0%	-88.2%
Cost of goods sold	4.2	37.3	18.3	-14.2
Gross profit	-4.2	-37.3	-17.7	14.2
Gross margin		-56471.2%	-3176.8%
Selling, general and administrative [+]	28.4	51.8	12.2	3.0
General and administrative	28.4	51.8	12.2	3.0
Research and development	47.6	71.4	20.6	10.7
Other operating expenses	-4.2	-35.4	-18.2	14.2
EBITDA [+]	-74.3	-124.0	-31.6
EBITDA growth	-40.1%	292.8%	131.1%
EBITDA margin		-187837.9%	-5667.0%
Depreciation and amortization	1.7	1.1	0.7
EBIT [+]	-76.0	-125.1	-32.3	-13.7
EBIT growth	-39.3%	287.4%	136.3%
EBIT margin		-189507.6%	-5795.7%
Interest expense, net [+]	-0.7	0.8	1.2
Interest expense	0.5	0.8	1.2
Interest income	1.3	0.0
Other income (expense), net [+]	0.0	-11.3	-6.5	-0.5
Gain (loss) on foreign currency transactions	0.0	0.0	-0.1
Change in fair value of warrants		0.2	0.0
Other non-ooperating expenses			7.7
Other	0.8	-12.1
Pre-tax income	-75.2	-137.2	-40.0	-14.2
Income taxes	0.0	0.0	0.0	0.1
Tax rate	0.0%	0.0%	0.0%
Net income	-75.2	-137.2	-40.0	-14.2
Net margin		-207840.9%	-7173.6%

Basic EPS [+]	($0.60)	($1.79)	($0.61)	($0.42)
Growth	-66.7%	194.2%	44.9%
Diluted EPS [+]	($0.60)	($1.79)	($0.61)	($0.42)
Growth	-66.7%	194.2%	44.9%

Shares outstanding (basic) [+]	125.9	76.6	65.6	33.9
Growth	64.4%	16.7%	93.9%
Shares outstanding (diluted) [+]	125.9	76.6	65.6	33.9
Growth	64.4%	16.7%	93.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.